

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PAR PHARMACEUTICAL, INC.,  
Petitioner,

v.

HORIZON THERAPEUTICS, INC.,  
Patent Owner.

---

Case IPR2017-01768  
Patent 9,095,559

---

**PETITIONER PAR PHARMACEUTICAL, INC.'S  
UPDATED EXHIBIT LIST**

*Mail Stop "PATENT BOARD"*  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**List of Exhibits and Abbreviations for Exhibits**

<b>EXHIBIT NO.</b>	<b>DESCRIPTION</b>	<b>ABBREVIATION (if applicable)</b>
1001	U.S. Patent No. 9,095,559 to Scharschmidt et al., filed February 22, 2013, issued August 4, 2015	the '559 Patent
1002	Declaration of Dr. Neal Sondheimer	
1003	<i>Curriculum vitae</i> of Dr. Neal Sondheimer	
1004	U.S. Patent Publication No. 2010/0008859, filed January 7, 2009, published January 14, 2010	the '859 Publication
1005	Moser et al., <i>Argininoscuccinic Aciduria Report of Two New Cases and Demonstration of Intermittent Elevation of Blood Ammonia</i> , 42 Am. J. Med. 9-26 (1967)	Moser
1006	Blau, Duran, Blaskovics, Gibson (editors), <i>Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases</i> , 261–276 (2d ed. 1996)	Blau
1007	Simell et al., <i>Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance</i> , 20 Pediatric Research, 1117–1121 (1986)	Simell
1008	Feillet et al., <i>Alternative Pathway Therapy for Urea Cycle Disorders</i> , 21 Suppl 1, 101-111 (1998)	Feillet

*IPR2017-01768*  
*Patent No. 9,095,559*  
*Par's Updated Exhibit List*

EXHIBIT NO.	DESCRIPTION	ABBREVIATION (if applicable)
1009	Scientific Discussion for Ammonaps, EMEA, 1-12 (2005)	Ammonaps
1010	Lee et al., <i>Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia control</i> , 100 Molecular Genetics and Metabolism, 221-228 (2010)	Lee
1011	Buphenyl Label	
1012	Prosecution History of U.S. Patent No. 8,404,215	the '215 Parent Patent
1013	Assignment History of U.S. Patent 8,642,012	
1014	'559 Patent Infringement Complaint with Return of Service	
1015	Fernandes et al., <i>Inborn Metabolic Diseases Diagnosis and Treatment</i> , 214-22 (J. Fernandes et al., eds., 3d ed. 2002)	Fernandes
1016	Leonard et al., <i>Hypothesis: Proposals for the Management of a Neonate at Risk of Hyperammonaemia Due to a Urea Cycle Disorder</i> , 167 Eur. J. Pediatr. 305-309 (2008)	Leonard 2008

<b>EXHIBIT NO.</b>	<b>DESCRIPTION</b>	<b>ABBREVIATION (if applicable)</b>
1017	Lichter-Konecki et al., <i>Ammonia Control in Children with Urea Cycle Disorders (UCDs): Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate</i> , 103 <i>Molecular Genetics and Metabolism</i> , 323-329 (2011)	Lichter-Konecki
1018	Pandya et al., <i>N-Acetylglutamate Synthetase Deficiency: Clinical and Laboratory Observations</i> , 14 <i>J. Inher. Metab. Dis.</i> 685-690 (1991)	Pandya
1019	U.S. Patent No. 5,968,979	the '979 patent
1020	McGuire et al., <i>Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis</i> , 51(6) <i>Hepatology</i> 2077-2085 (2010)	McGuire
1021	Diaz et al., <i>Phase 3 Blinded, Randomized, Crossover Comparison of Sodium Phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB): Ammonia (NH<sub>3</sub>) Control in Adults with Urea Cycle Disorders (UCDs)</i> , 102 <i>Molecular Genetics and Metabolism</i> 276-77 (2011)	Diaz
1022	Barsotti, <i>Measurement of Ammonia in Blood</i> , 138 <i>J. Pediatrics</i> , S11-S20 (2001)	Barsotti

**IPR2017-01768**  
**Patent No. 9,095,559**  
**Par's Updated Exhibit List**

EXHIBIT NO.	DESCRIPTION	ABBREVIATION (if applicable)
1023	Yajima, et al., <i>Diurnal Fluctuations of Blood Ammonia Levels in Adult-Type Citrullinemia</i> , 137 Tokohu J. Ex/ Med, 213-220 (1982)	Yajima
1024	Batshaw, et al., <i>Treatment of Carbamyl Phosphate Synthetase Deficiency with Keto Analogues of Essential Amino Acids</i> , 292 New Eng. J. Med. 1085-90 (1975)	Batshaw
1025	Brusilow, <i>Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion</i> , 29 Pediatric Research, 147-150 (1991)	Brusilow '91
1026	Enns Deposition Ex. 1026, Fernandes et al., <i>Inborn Metabolic Diseases Diagnosis and Treatment</i> , 214-22 (J. Fernandes et al., eds., 3d ed. 2000)	
1027	Transcript of July 18, 2018 Deposition of Dr. Gregory M. Enns	
1028	Reply Declaration of Dr. Neal Sondheimer	
1029	Affidavit of Christopher M. Gallo in Support of Petitioner's Motion to Accept Filing of Petitioner's Reply to Patent Owner's Response to the Petition on August 16, 2018 Under 37 C.F.R. § 42.6(B)	

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.